American Regent
As of the edition of 20 October 2026, American Regent runs 9 drugs, 8 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Went quiet | 1 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Paclitaxel | none listed | 0 |
| Furosemide | none listed | 2 |
| Ferric carboxymaltose | Ends 2027 (patent) | 0 |
| Vasopressin | none listed | 0 |
| Zinc sulfate | none listed | 0 |
| Iron sucrose | none listed | 0 |
| Iron dextran | none listed | 0 |
| Selenious acid | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Blood and lymph: 19 trials led
- Cancer: 5 trials led
- Nutrition and metabolism: 5 trials led